HARS1 — Histidyl-tRNA Synthetase 1

HARS1 — Histidyl-tRNA Synthetase 1

<div class="infobox infobox-gene">
<div class="infobox-header">HARS1</div>
<div class="infobox-row"><strong>Full Name:</strong> Histidyl-tRNA Synthetase 1</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 5q31.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 3065</div>
<div class="infobox-row"><strong>OMIM:</strong> 142810</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000121405</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P12001</div>
<div class="infobox-row"><strong>Protein Length:</strong> 509 amino acids</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Charcot-Marie-Tooth disease type 2W, Usher syndrome, mitochondrial translation disorders, autoimmune responses</div>
</div>

Overview

HARS1 — Histidyl-tRNA Synthetase 1

<div class="infobox infobox-gene">
<div class="infobox-header">HARS1</div>
<div class="infobox-row"><strong>Full Name:</strong> Histidyl-tRNA Synthetase 1</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 5q31.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 3065</div>
<div class="infobox-row"><strong>OMIM:</strong> 142810</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000121405</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P12001</div>
<div class="infobox-row"><strong>Protein Length:</strong> 509 amino acids</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Charcot-Marie-Tooth disease type 2W, Usher syndrome, mitochondrial translation disorders, autoimmune responses</div>
</div>

Overview

HARS1 encodes histidyl-tRNA synthetase 1 (HisRS), an essential enzyme in protein synthesis that catalyzes the attachment of histidine to its cognate tRNA (tRNA^His) [1](https://pubmed.ncbi.nlm.nih.gov/23480851/). This aminoacylation reaction is a critical step in translation, ensuring accuracy and fidelity of protein biosynthesis. HARS1 is a member of the class II aminoacyl-tRNA synthetase family, characterized by conserved structural motifs and catalytic mechanisms.

Beyond its canonical role in translation, HARS1 has been implicated in diverse extra-translational functions including RNA splicing, cell signaling, immune regulation, and mitochondrial function [2](https://doi.org/10.1016/j.tcb.2017.01.003). The discovery of disease-causing mutations in HARS1 has established its importance in peripheral neuropathy and neuromuscular disorders.

Molecular Biology and Structure

Gene Organization

The HARS1 gene spans approximately 14 kb on chromosome 5q31.3 and consists of 19 exons. The coding sequence encodes a protein of 509 amino acids with a molecular weight of approximately 56 kDa. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns.

Protein Domain Architecture

The HARS1 protein contains several functional domains:

HARS1 functions as a homodimer, with dimerization required for full enzymatic activity. Each monomer contains the signature motifs characteristic of class II aminoacyl-tRNA synthetases.

Enzyme Mechanism

The aminoacylation reaction proceeds through two catalytic steps:

The enzyme exhibits high fidelity for both histidine and tRNA^His, with proofreading mechanisms that prevent mischarging. The class II active site contains three conserved motifs: motif 1 (loop enclosing the ATP binding pocket), motif 2 (involved in amino acid binding), and motif 3 (interacts with the tRNA acceptor stem).

Function

Canonical Translation Function

HARS1 is essential for cytosolic protein synthesis:

• Provides histidyl-tRNA for ribosomal translation
• Ensures accurate codon-anticodon matching
• Maintains translational fidelity through editing functions
• Required for cell viability in all tissues

Mitochondrial Function

A subset of HARS1 localizes to mitochondria where it participates in mitochondrial translation [3](https://pubmed.ncbi.nlm.nih.gov/25786211/). While mitochondria have their own set of aminoacyl-tRNA synthetases, HARS1 may serve specialized functions in mitochondrial-nuclear crosstalk. Mitochondria contain a dedicated histidyl-tRNA synthetase (HARS2) encoded in the mitochondrial genome, but nuclear-encoded HARS1 may have roles in mitochondrial import or signaling.

Extra-Translational Functions

HARS1 exhibits several non-canonical functions:

Disease Associations

Charcot-Marie-Tooth Disease Type 2W (CMT2W)

CMT2W is an axonal form of hereditary peripheral neuropathy caused by HARS1 mutations [4](https://pubmed.ncbi.nlm.nih.gov/26703874/):

Clinical Features

• Onset in adolescence or early adulthood
• Distal muscle weakness and atrophy (starting in feet/legs)
• Sensory loss, particularly in lower extremities
• Foot deformities (pes cavus, hammertoes)
• Reduced or absent deep tendon reflexes
• Variable progression
• Sometimes associated with hearing loss

Genetics

• Autosomal dominant inheritance pattern
• Multiple pathogenic variants identified (Y454C, S603F, R308C)
• Variable expressivity and incomplete penetrance
• De novo mutations observed

Pathogenesis

• Axonal degeneration of peripheral neurons
• Impaired mitochondrial function in axons
• Defects in protein quality control
• Altered aminoacylation fidelity
• Disruption of axonal transport

Usher Syndrome

Rare HARS1 variants have been associated with Usher syndrome:

• Sensorineural hearing loss
• Retinitis pigmentosa (progressive vision loss)
• Vestibular dysfunction
• Combined auditory and visual impairment

Mitochondrial Disorders

Certain HARS1 variants affect mitochondrial translation:

• Impaired OXPHOS function
• Reduced ATP production
• Increased oxidative stress
• Encephalomyopathic presentations

Autoimmune Conditions

HARS1 can be targeted by autoantibodies:

• Anti-HARS antibodies in polymyositis/dermatomyositis
• Interstitial lung disease association
• Raynaud's phenomenon
• Clinical myopathy with autoantibodies

Neurodevelopmental Disorders

Some HARS1 variants are associated with:

• Intellectual disability
• Developmental delay
• Autism spectrum features
• Speech delays

Expression Pattern

Tissue Distribution

HARS1 is ubiquitously expressed with highest levels in:

| Tissue | Expression Level | Notes |
|--------|------------------|-------|
| Brain | High | Cerebral cortex, cerebellum |
| Spinal Cord | High | Motor and sensory neurons |
| Peripheral Nerves | High | Schwann cells, neurons |
| Heart | High | Continuous function |
| Skeletal Muscle | High | Energy demand |
| Liver | Moderate | Metabolic function |
| Kidney | Moderate | Housekeeping |
| Lung | Moderate | Housekeeping |

Cellular Localization

HARS1 localizes to:

• Cytosol (majority)
• Mitochondria (subset)
• Nucleus (lower levels)
• Extracellular (secreted form in some contexts)

Brain Expression

In the central nervous system, HARS1 is expressed in:

• Pyramidal neurons (cortex)
• Purkinje cells (cerebellum)
• Motor neurons (spinal cord)
• Sensory neurons (dorsal root ganglia)
• Glial cells (astrocytes, oligodendrocytes)

Interaction Network

Protein Interactions

HARS1 interacts with several proteins:

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| tRNA^His | Direct substrate | Aminoacylation |
| Aminoacyl-tRNA synthetase complexes | Complex formation | Editing, localization |
| EF-1α | Functional | Translation elongation |
| Ribosomal proteins | Functional | Translation machinery |
| Mitochondrial proteins | Indirect | Mitochondrial function |

Genetic Interactions

HARS1 interacts genetically with:

• Other aminoacyl-tRNA synthetases
• Mitochondrial function genes
• Axonal transport genes
• Translation fidelity factors

Therapeutic Implications

Current Treatment Strategies

Treatment for HARS1-related neuropathy is primarily supportive:

Emerging Approaches

Challenges

• Blood-brain barrier limits CNS delivery
• Peripheral nerve targeting required
• Variable mutation severity
• Late-stage intervention limitations
• Essential function requires careful targeting

Research Directions

Current Knowledge Gaps

• Structure-function relationships for pathogenic mutations
• Mechanisms of axonal degeneration
• Natural history of CMT2W
• Biomarkers for disease progression
• Tissue-specific vulnerabilities

Future Research Priorities

Animal Models

Mouse Models

| Model | Description | Phenotype |
|-------|-------------|-----------|
| Hars1 knockout | Complete deletion | Embryonic lethal |
| Hars1 conditional KO | Tissue-specific | Under investigation |
| Hars1 knock-in | Disease mutations | Modeling CMT2W |

Functional Studies

• Drosophila: Synaptic transmission defects
• Zebrafish: Developmental abnormalities
• Cell models: Axonal transport impairment

Key Publications

References

See Also

• [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)
• [Aminoacyl-tRNA Synthetases](/mechanisms/aminoacyl-trna-synthesis)
• [Protein Translation](/mechanisms/protein-translation)
• [Mitochondrial Translation](/mechanisms/mitochondrial-translation)
• [Peripheral Neuropathy](/diseases/peripheral-neuropathy)
• [Axonal Degeneration](/mechanisms/axonal-degeneration)
• [Mitochondrial Disease](/diseases/mitochondrial-diseases)
• [Usher Syndrome](/diseases/usher-syndrome)

External Links

• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3065)
• [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121405)
• [UniProt](https://www.uniprot.org/uniprot/P12001)
• [OMIM](https://www.omim.org/entry/142810)

Pathway Diagram

The following diagram shows the key molecular relationships involving HARS1 — Histidyl-tRNA Synthetase 1 discovered through SciDEX knowledge graph analysis: